



Epiroc AB (publ)

(incorporated in Sweden as a public company with limited liability under registration number 556041-2149)

€1,500,000,000

Euro Medium Term Note Programme

This document constitutes a supplement (the “**Supplement**”) for the purposes of Article 23 of Regulation (EU) 2017/1129 (the “**Prospectus Regulation**”), to the base prospectus of Epiroc AB (publ) (the “**Issuer**”), dated 26 July 2023 as first supplemented on 12 December 2023 (the “**Base Prospectus**”), which constitutes a base prospectus for the purposes of Article 8 of the Prospectus Regulation.

This Supplement is supplemental to, and should be read in conjunction with, the Base Prospectus.

This Supplement has been approved as a supplement by the Central Bank of Ireland, as competent authority under the Prospectus Regulation. The Central Bank of Ireland only approves this Supplement as meeting the standards of completeness, comprehensibility and consistency imposed by the Prospectus Regulation. Such approval should not be considered as an endorsement of the Issuer or of the quality of the Notes that are the subject of the Base Prospectus, as supplemented. Investors should make their own assessment as to the suitability of investing in the Notes.

The Issuer accepts responsibility for the information contained in this Supplement. To the best of the knowledge of the Issuer, the information contained in this Supplement is in accordance with the facts and does not omit anything likely to affect the import of such information.

Purpose of this Supplement

This Supplement has been prepared and published for the purposes of (a) incorporating by reference the Issuer’s interim unaudited consolidated financial statements in respect of the twelve months ended 31 December 2023 in the Base Prospectus and (b) including a new “Significant/Material Change” statement.

Unless the context otherwise requires, terms defined in the Base Prospectus shall have the same meaning when used in this Supplement. To the extent that there is any inconsistency between (a) any statement in this Supplement, or any statement incorporated by reference into the Base Prospectus by this Supplement and (b) any other statement in, or incorporated by reference into, the Base Prospectus, the statements in (a) above will prevail.

Save as disclosed in this Supplement and the supplement dated 12 December 2023, there has been no other significant new factor, material mistake or material inaccuracy relating to information included in the Base Prospectus since the publication of the Base Prospectus.

This Supplement is available for viewing on the website of Epiroc at www.epirocgroup.com.

The date of this Supplement is 15 February 2024.

DOCUMENTS INCORPORATED BY REFERENCE

The information set out below supplements the section of the Base Prospectus headed “*DOCUMENTS INCORPORATED BY REFERENCE*” on page 22 of the Base Prospectus, adding the following additional document to be incorporated by reference as the fifth paragraph in the list, with all subsequent paragraphs to be renumbered accordingly:

- (5) the interim unaudited consolidated report of the Issuer in respect of the twelve months ended 31 December 2023:

<https://www.epirocgroup.com/content/dam/epiroc/corporate/documents/quarterly-results-presentations-/2023-q4/Epiroc%20Interim%20report%20Q4%202023.pdf>.

GENERAL INFORMATION

The third paragraph of the section of the Base Prospectus headed “*GENERAL INFORMATION*” on page 85 of the Base Prospectus shall be updated as follows:

- (3) There has been no significant change in the financial performance or financial position of the Issuer or of the Group since 31 December 2023, and there has been no material adverse change in the prospects of the Issuer or of the Group since 31 December 2022.